ArticleAntioxidants (Basel, Switzerland)2022
The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis.
Open access · goldAbstract read
In one paragraph
Article in Antioxidants (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Inhibition of calreticulin by protein nanoparticles carrying antisense oligonucleotides reduce gene expression and infection ofNanomedicine (London, England) · 2025Article
- CD44 Participates to Extramedullary Haematopoiesis Onset by Mediating the Interplay Between Monocytes and Haematopoietic Stem Cells in Myelofibrosis.Journal of cellular and molecular medicine · 2025Article
- Chronic Inflammation in Primary Myelofibrosis: In-Depth Insights Into Pathogenesis and Promising Anti-Inflammatory Therapeutic Strategies.Mediators of inflammation · 2025Review
- Article
- Prognostic and Predictive Models in Myelofibrosis.Current hematologic malignancy reports · 2024Review
- The Role of Mutated Calreticulin in the Pathogenesis ofInternational journal of molecular sciences · 2024Article
- Assessment of Total Antioxidant Capacity, 8-Hydroxy-2'-deoxy-guanosine, the Genetic Landscape, and Their Associations inInternational journal of molecular sciences · 2024Article
- Targeted Metabolomics Highlights Dramatic Antioxidant Depletion, Increased Oxidative/Nitrosative Stress and Altered Purine and Pyrimidine Concentrations in Serum of Primary Myelofibrosis Patients.Antioxidants (Basel, Switzerland) · 2024Article
- Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model.Leukemia · 2023Article
- Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective.International journal of molecular sciences · 2022Review
- Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms.Current hematologic malignancy reports · 2022Review
- Cardiovascular Disease in Myeloproliferative Neoplasms:JACC. CardioOncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 5 institutions in 1 country.
Elena GenoveseCentre for Regenerative Medicine, Life Sciences Department, University of Modena and Reggio Emilia, 41125 Modena, Italy.ORCID 0000-0002-0188-0295
Margherita MirabileCentre for Regenerative Medicine, Life Sciences Department, University of Modena and Reggio Emilia, 41125 Modena, Italy.
Sebastiano RontauroliCentre for Regenerative Medicine, Life Sciences Department, University of Modena and Reggio Emilia, 41125 Modena, Italy.
Stefano SartiniCentre for Regenerative Medicine, Life Sciences Department, University of Modena and Reggio Emilia, 41125 Modena, Italy.
Sebastian FantiniCentre for Regenerative Medicine, Life Sciences Department, University of Modena and Reggio Emilia, 41125 Modena, Italy.
Lara TavernariCentre for Regenerative Medicine, Life Sciences Department, University of Modena and Reggio Emilia, 41125 Modena, Italy.
Monica MaccaferriDepartment of Laboratory Medicine and Pathology, Diagnostic Hematology and Clinical Genomics, AUSL/AOU Policlinico, 41124 Modena, Italy.
Paola GuglielmelliCenter of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, University of Florence, Careggi University Hospital, 50134 Florence, Italy.ORCID 0000-0003-1809-284X
Elisa BianchiCentre for Regenerative Medicine, Life Sciences Department, University of Modena and Reggio Emilia, 41125 Modena, Italy.ORCID 0000-0002-6110-5944
Sandra ParentiCentre for Regenerative Medicine, Life Sciences Department, University of Modena and Reggio Emilia, 41125 Modena, Italy.
Chiara CarrettaCentre for Regenerative Medicine, Life Sciences Department, University of Modena and Reggio Emilia, 41125 Modena, Italy.ORCID 0000-0001-5952-0818
Selene MalliaCentre for Regenerative Medicine, Life Sciences Department, University of Modena and Reggio Emilia, 41125 Modena, Italy.
Sara CastellanoCenter for Genome Research, University of Modena and Reggio Emilia, 41125 Modena, Italy.ORCID 0000-0001-6786-7854
Corrado ColasanteDepartment of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AUSL/AOU Policlinico, 41124 Modena, Italy.ORCID 0000-0002-5436-7794
Manjola BalliuCenter of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, University of Florence, Careggi University Hospital, 50134 Florence, Italy.
Niccolò BartalucciCenter of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, University of Florence, Careggi University Hospital, 50134 Florence, Italy.
Raffaele PalmieriDepartment of Biomedicine and Prevention, University of Tor Vergata, 00133 Rome, Italy.ORCID 0000-0003-2855-8121
Tiziana OttoneDepartment of Biomedicine and Prevention, University of Tor Vergata, 00133 Rome, Italy.
Barbara MoraDivision of Hematology, Ospedale ASST Sette Laghi, University of Insubria, 21110 Varese, Italy.
Leonardo PotenzaDepartment of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AUSL/AOU Policlinico, 41124 Modena, Italy.
Francesco PassamontiDivision of Hematology, Ospedale ASST Sette Laghi, University of Insubria, 21110 Varese, Italy.
Maria Teresa VosoDepartment of Biomedicine and Prevention, University of Tor Vergata, 00133 Rome, Italy.ORCID 0000-0002-6164-4761
Mario LuppiDepartment of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AUSL/AOU Policlinico, 41124 Modena, Italy.
Alessandro Maria VannucchiCenter of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, University of Florence, Careggi University Hospital, 50134 Florence, Italy.ORCID 0000-0001-5755-0730
Enrico TagliaficoCenter for Genome Research, University of Modena and Reggio Emilia, 41125 Modena, Italy.ORCID 0000-0003-0981-2542
Rossella ManfrediniCentre for Regenerative Medicine, Life Sciences Department, University of Modena and Reggio Emilia, 41125 Modena, Italy.ORCID 0000-0003-0660-6110
On Behalf Of The Mynerva MYeloid NEoplasms Research Venture Airc
University of Modena and Reggio Emilia · ITUniversity of Florence · ITUniversity of Rome Tor Vergata · ITUniversity of Insubria · ITAzienda Ospedaliero-Universitaria di Modena · IT
Funding
Italian Association for Cancer Research 19818Italian Association for Cancer Research 21267Ministero della Salute RF-2016-02362930Ministry of Education, Universities and Research 2017WXR7ZT
Abstract
Myelofibrosis (MF) is the Philadelphia-negative myeloproliferative neoplasm characterized by the worst prognosis and no response to conventional therapy. Driver mutations in
Indexed as
8-hydroxy-2′-deoxy-guanosinecalreticulinjanus kinase 2myelofibrosisoxidative stressreactive oxygen speciessuperoxide dismutasetotal antioxidant capacity
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.